Monitor IPO pricing and Nasdaq listing (VOGX). The Phase 2b EMERGE study results in 2027 are the next major catalyst. Amylyx's Phase 3 PBH readout in 2026 could shift competitive dynamics. Post-IPO, watch for insider lockup expirations and additional capital needs for Phase 3.
Executive Summary
Vogenx filed Amendment No. 2 to its S-1 registration statement, confirming the IPO at 6,250,000 shares priced between $11.00-$13.00 per share (midpoint $12.00) for listing on Nasdaq under VOGX. The clinical-stage biopharma focused on its SGLT1 inhibitor mizagliflozin for post-bariatric hypoglycemia and gastroparesis expects net proceeds of ~$67.8M, extending runway through 2028, though significant additional capital will be needed for Phase 3 trials. This amendment finalizes offering size and price range after the prior S-1/A filed 12 days ago.
Key Financial Metrics
Key Facts
- Offering 6,250,000 shares at $11-$13 per share (midpoint $12.00) for Nasdaq listing under VOGX
- Estimated net proceeds of ~$67.8M ($78.2M with overallotment) to fund mizagliflozin development through 2028
- Cash and cash equivalents of $251K as of March 31, 2026; accumulated deficit of $11.3M
- Net loss of $475K for Q1 2026; no revenue generated; auditor includes going concern explanatory paragraph
- Lead candidate mizagliflozin completed Phase 2 PBH studies; Phase 2b EMERGE study starting in 2026; gastroparesis Phase 2 planned for 2027
- Material weaknesses in internal control over financial reporting identified
- Competitor Amylyx initiated Phase 3 PBH trial in 2025 with results expected in 2026
Financial Impact
IPO raises ~$67.8M net proceeds, extending cash runway through 2028 but insufficient for Phase 3 trials
Risk Factors
- Clinical trial failure or delays in mizagliflozin development
- Need for substantial additional capital beyond IPO proceeds to fund Phase 3 trials
- Competition from Amylyx's avexitide (Phase 3 PBH) and other PBH candidates
- Material weaknesses in internal controls may affect financial reporting reliability
- Limited operating history with no approved products or revenue
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001185185-26-003353 |
| Document: vogenxex23-1.htm | 0001185185-26-003353 |
| Document: 0001185185-26-003353-index-headers.html | 0001185185-26-003353 |
| Document: 0001185185-26-003353-index.html | 0001185185-26-003353 |
| Document: 0001185185-26-003353.txt | 0001185185-26-003353 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $17.56 | awaiting T+20 | — | $19.16 (+9.11%) |
Aug 17, 2026 10w ago | Press Release | $15.75 $32.21 | ▲ +104.51% | ▲ +106.49% | $19.16 (+21.65%) |
Aug 11, 2026 10w ago | 3 | $13.00 $29.86 | ▲ +129.69% | ▲ +131.59% | $19.16 (+47.38%) |
Aug 11, 2026 10w ago | 3 | $13.00 $29.86 | ▲ +129.69% | ▲ +131.59% | $19.16 (+47.38%) |
Aug 10, 2026 11w ago | S-1/A | — | awaiting T+20 | — | — |
Jul 29, 2026 12w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers